First Trust NYSE Arca Biotechnology Index Fund FBT

El fondo de inversión busca obtener resultados de inversión que correspondan generalmente al precio y rendimiento (antes de las tarifas y gastos del fondo) de un índice bursátil llamado NYSE Arca Biotechnology IndexSM. El fondo normalmente invertirá al menos el 90% de sus activos netos (incluyendo préstamos de inversión) en acciones comunes que componen el índice. El índice es un índice ponderado por igual en dólares diseñado para medir el rendimiento de una muestra de empresas en la industria de la biotecnología que están principalmente involucradas en el uso de procesos biológicos para desarrollar productos o brindar servicios.

• Zacks Investment Research 21 sept

  Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

  Biotech companies are increasingly directing capital toward oncology therapeutics, with over $3.9 billion of venture capital flowing into cancer and immunology drug developers in H1 2026. The global oncology drugs market is projected to grow from $256.5 billion in 2025 to nearly $700 billion by 2034, prompting investors to consider biotech ETFs for diversified exposure to this growth opportunity rather than individual stocks.

  

• Zacks Investment Research 1 sept

  Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

  The First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed fund offering broad exposure to the biotech sector with $2.91 billion in assets. The ETF has delivered strong performance with 29.36% gains year-to-date and 55.34% over the past year, though it carries higher risk with a beta of 0.66 and 20.71% standard deviation. With a 0.55% expense ratio and a Zacks ETF Rank of 2 (Buy), FBT is positioned as a solid option for biotech exposure, though larger competitors like IBB and XBI offer lower expense ratios.

  

• The Motley Fool 23 jul

  Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

  First Trust NYSE Arca Biotechnology Index Fund (FBT) offers concentrated exposure to 30 biotech stocks with 51.6% 1-year returns but higher volatility and a 0.55% expense ratio. Vanguard Health Care ETF (VHT) provides broader diversification across 400+ healthcare companies with lower costs (0.09% expense ratio) and dividend yield, making it better for long-term stability. FBT suits investors with high risk tolerance and biotech conviction, while VHT is recommended for those seeking healthcare as a portfolio stabilizer.

  

• The Motley Fool 21 jul

  Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?

  iShares Global Healthcare ETF (IXJ) offers broad diversification across 110 global healthcare companies with a lower 0.40% expense ratio, while First Trust NYSE Arca Biotechnology Index Fund (FBT) concentrates on 30 biotech companies with higher growth potential but greater volatility. IXJ suits defensive investors seeking stable exposure to established pharma giants, while FBT appeals to those betting on biotech breakthroughs despite higher risk.

  

• The Motley Fool 12 jul

  Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

  First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.